Vol 28, No 5 (2021)
Letter to the Editor
Published online: 2021-07-07

open access

Page views 12185
Article views/downloads 585
Get Citation

Connect on Social Media

Connect on Social Media

Mortality reduction with levosimendan in patients with heart failure: Current evidence is underpowered

Filippo Sanfilippo1, Luigi La Via1, Federica Merola1, Marinella Astuto1
Pubmed: 34240399
Cardiol J 2021;28(5):798-799.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Jaguszewski MJ, Gasecka A, Targonski R, et al. Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis. Cardiol J. 2021; 28(3): 492–493.
  2. Sanfilippo F, Knight JB, Scolletta S, et al. Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery: a systematic review and meta-analysis. Crit Care. 2017; 21(1): 252.
  3. Afshari A, Wetterslev J. When may systematic reviews and meta-analyses be considered reliable? Eur J Anaesthesiol. 2015; 32(2): 85–87.
  4. Barili F, Parolari A, Kappetein PA, et al. Statistical Primer: heterogeneity, random- or fixed-effects model analyses? Interact Cardiovasc Thorac Surg. 2018; 27(3): 317–321.
  5. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007; 297(17): 1883–1891.